Navigation Links
Evotec Starts Phase II in Smoking Cessation with EVT 302
Date:2/28/2008

ination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and preclinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties' ability to complete the transaction because conditions to the closing of the transaction may not be satisfied; the failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; general worldwide economic conditions and related uncertainties; future legislative, regulatory, or tax changes as well as other economic, business and/or competitive factors; and the effect of exchange rate fluctuations on international operations. The risks included above are not exhaustive.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. Evotec Reports Third Quarter 2007 Results
6. Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board
7. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
8. Evotec to Present at the BIO CEO & Investor Conference 2008 in New York
9. Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million
10. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... -- Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property development ... property, today announced a litigation update. In ... Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in the ... Virginia , the Court issued a ... claims in favor of the Defendants on the one ...
(Date:7/1/2015)... TRIANGLE PARK, N.C. and ... agricultural research firm AgBiome, and Genective, key developer ... to accelerate the discovery of new generations of ... traits for insect control to counter the realities ... partner with Genective, aligning AgBiome,s unique insect control ...
(Date:7/1/2015)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced that the company will host ... p.m. EDT following its presentation of RVT-101 clinical ... (AAIC). The event will include ... Lawrence Friedhoff , Chief Development Officer, will present ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) ... CTI’ new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... device that will increase healthcare worker safety and reduce financial costs. , CTI ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... ROCKVILLE, Md., Oct. 31 OriGene Technologies, Inc.,announces ... now in,a GFP (green fluorescence protein) vector, enabling ... over 25,000 human ORF,(open reading frame) clones and ... vector., In early October, the 2008 Nobel ...
... ThermoGenesis,Corp. (Nasdaq: KOOL ), a leading supplier of ... today it will report,financial results for the fiscal first ... Company,s Conference Call and Webcast, Management will ... PM Pacific (5:00 PM Eastern) to review the fiscal ...
... Sharps Compliance Corp. (OTC,Bulletin Board: SCOM) ("Sharps" ... solutions for small quantity generators of medical,waste, today ... the,Company,s President and Chief Operating Officer, effective October ... of the Company,s Board of Directors,since October of ...
Cached Biology Technology:OriGene Announces 37,000 ORF cDNA Clones in a GFP Vector 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008 2Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer 2Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer 3
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:7/2/2015)... , June 25, 2015 ... addition of the "Next Generation Biometrics Market by ... 2020" report to their offering. The ... Billion by 2020, at a CAGR of 17.9% between ... the leading application for the market. Safran SA ...
(Date:7/2/2015)... Sweden , July 2, 2015 ... sensors FPC1025, FPC1035, FPC1145 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... 2015. The sensors will be used by smartphone manufacturers in ... MSEK is included in the communicated revenue guidance of approximately ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... tool, a searchable database known ... in Florida," was developed by ... the University of Florida, the ... the U.S. Geological Survey, and ...
... Obesity is a major contributor to heart disease that substantially ... researching the impact of obesity and weight loss on the ... the country,s problem is only going to get worse, said ... Medical College of Georgia Section of Cardiology at Georgia Health ...
... lack the ability to adapt effectively to predicted increases ... near future, according to new research. In ... National Academy of Sciences , researchers from Monash University, ... many species of fruit fly appear to be constrained ...
Cached Biology News:Obesity is major contributor to heart disease, impediment to diagnosis and treatment 2Obesity is major contributor to heart disease, impediment to diagnosis and treatment 3Evolutionary straitjacket means flies can't take the heat 2
Goat polyclonal to Centaurin alpha 2**...
... signal and low background ,This solution greatly ... times higher than obtained with conventional methods. ... primary and secondary antibodies, which can suppress ... , Wide versatility ,It is applicable ...
Monocarboxylate (lactate) transporter 2...
Mouse anti human pro-Relaxin-2...
Biology Products: